Anzeige
Mehr »
Montag, 21.07.2025 - Börsentäglich über 12.000 News
Alarm am Metallmarkt: Kupfer unter Strom: USA rüsten sich - was das für Anleger bedeutet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XD3D | ISIN: US7613301099 | Ticker-Symbol: N/A
Frankfurt
05.02.25 | 16:06
3,420 Euro
0,00 % 0,000
1-Jahres-Chart  (nicht börsennotiert)
REVANCE THERAPEUTICS INC Chart 1 Jahr

Aktuelle News zur REVANCE THERAPEUTICS

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.05.Revance Names New CEO to Drive Next Phase in Aesthetic Innovation3
18.02.Revance Therapeutics, Inc. - 15-12G, Securities registration termination1
REVANCE THERAPEUTICS Aktie jetzt für 0€ handeln
07.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.02.2025759The following instruments on Boerse Frankfurt do have their last trading day on 07.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.02.2025ISIN NameCA09226M1005 BLACK...
► Artikel lesen
06.02.Crown Labs schließt Übernahme von Revance Therapeutics ab1
06.02.Crown Laboratories, Inc.: Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics245The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn., Feb. 6, 2025...
► Artikel lesen
06.02.NSE - Revance Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities-
06.02.Revance Therapeutics, Inc. - 8-K, Current Report-
06.02.XFRA RTI: AUSSETZUNG/SUSPENSION241DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILREVANCE THERAPEUT.DL-...
► Artikel lesen
21.01.Dermata Therapeutics: Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari with Daxxify847The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari with Daxxify® to treat primary axillary hyperhidrosis -If successful, the Companies may explore clinical development...
► Artikel lesen
21.01.Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer122JOHNSON CITY & NASHVILLE, Tenn.--(BUSINESS WIRE)--Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that, on January 17, 2025, they amended...
► Artikel lesen
13.01.Crown Laboratories, Inc.: Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.408JOHNSON CITY, Tenn., Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today...
► Artikel lesen
09.12.24Crown Laboratories, Inc.: Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement217JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance...
► Artikel lesen
07.11.24Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update183NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance," the "Company" or "our"), today reported financial results for the third quarter ended September 30, 2024...
► Artikel lesen
12.08.24XFRA RTI: WIEDERAUFNAHME/RESUMPTION290FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
12.08.24XFRA RTI: AUSSETZUNG/SUSPENSION153DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILREVANCE THERAPEUT.DL-...
► Artikel lesen
12.08.24Crown Laboratories, Inc.: Crown Laboratories and Revance Announce Entry Into Merger Agreement672Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare companyBrings together two high-quality, complementary product lines Combined company's flagship...
► Artikel lesen
08.08.24Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update106NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update. Financial...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten